Remark: A phase II, open-label, multicenter study of orally administered romaciclib (RVU120) for the treatment of anemia in patients with lower-risk myelodysplastic neoplasms (LR-MDS)Uwe Platzbecker, Valeria Santini, Sophie Dimicoli Salazar et al.|Blood|2025Cited by 0